These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34208839)

  • 1. Is HSD17B13 Genetic Variant a Protector for Liver Dysfunction? Future Perspective as a Potential Therapeutic Target.
    Motomura T; Amirneni S; Diaz-Aragon R; Faccioli LAP; Malizio MR; Coard MC; Kocas-Kilicarslan ZN; Frau C; Haep N; Ostrowska A; Florentino RM; Soto-Gutierrez A
    J Pers Med; 2021 Jun; 11(7):. PubMed ID: 34208839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
    Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
    Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric non-alcoholic fatty liver disease and kidney function: Effect of
    Di Sessa A; Umano GR; Cirillo G; Passaro AP; Verde V; Cozzolino D; Guarino S; Marzuillo P; Miraglia Del Giudice E
    World J Gastroenterol; 2020 Sep; 26(36):5474-5483. PubMed ID: 33024398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Tanaka S; Mori K; Okanoue T; Itoh Y
    Liver Int; 2020 Jul; 40(7):1686-1692. PubMed ID: 32342668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.
    Ma Y; Belyaeva OV; Brown PM; Fujita K; Valles K; Karki S; de Boer YS; Koh C; Chen Y; Du X; Handelman SK; Chen V; Speliotes EK; Nestlerode C; Thomas E; Kleiner DE; Zmuda JM; Sanyal AJ; ; Kedishvili NY; Liang TJ; Rotman Y
    Hepatology; 2019 Apr; 69(4):1504-1519. PubMed ID: 30415504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort.
    Ting YW; Kong AS; Zain SM; Chan WK; Tan HL; Mohamed Z; Pung YF; Mohamed R
    Clin Mol Hepatol; 2021 Jul; 27(3):486-498. PubMed ID: 33618508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease.
    Sun DQ; Wang TY; Zheng KI; Zhang HY; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Jin Y; Zheng MH
    Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1822-1831. PubMed ID: 33853719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 17-Beta-Hydroxysteroid Dehydrogenase 13 Loss of Function Does Not Confer Protection to Nonalcoholic Fatty Liver Disease in Indian Population.
    Govardhan B; Anand VK; Nagaraja Rao P; Balachandran Menon P; Mithun S; Sasikala M; Sowmya TR; Anuradha S; Smita CP; Nageshwar Reddy D; Ravikanth V
    J Clin Exp Hepatol; 2024; 14(4):101371. PubMed ID: 38523737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease.
    Liu WY; Eslam M; Zheng KI; Ma HL; Rios RS; Lv MZ; Li G; Tang LJ; Zhu PW; Wang XD; Byrne CD; Targher G; George J; Zheng MH
    J Clin Transl Hepatol; 2021 Apr; 9(2):194-202. PubMed ID: 34007801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort
    Anstee QM; Darlay R; Cockell S; Meroni M; Govaere O; Tiniakos D; Burt AD; Bedossa P; Palmer J; Liu YL; Aithal GP; Allison M; Yki-Järvinen H; Vacca M; Dufour JF; Invernizzi P; Prati D; Ekstedt M; Kechagias S; Francque S; Petta S; Bugianesi E; Clement K; Ratziu V; Schattenberg JM; Valenti L; Day CP; Cordell HJ; Daly AK;
    J Hepatol; 2020 Sep; 73(3):505-515. PubMed ID: 32298765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rs72613567: TA Variant in the Hydroxysteroid 17-beta Dehydrogenase 13 Gene Reduces Liver Damage in Obese Children.
    Di Sessa A; Umano GR; Cirillo G; Marzuillo P; Arienzo MR; Pedullà M; Miraglia Del Giudice E
    J Pediatr Gastroenterol Nutr; 2020 Mar; 70(3):371-374. PubMed ID: 31789772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics/Latinos.
    Kallwitz E; Tayo BO; Kuniholm MH; Daviglus M; Zeng D; Isasi CR; Cotler SJ
    Liver Int; 2020 Apr; 40(4):889-893. PubMed ID: 31965669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.
    Hudert CA; Adams LA; Alisi A; Anstee QM; Crudele A; Draijer LG; Furse S; Hengstler JG; Jenkins B; Karnebeek K; Kelly DA; Koot BG; Koulman A; Meierhofer D; Melton PE; Mori TA; Snowden SG; van Mourik I; Vreugdenhil A; Wiegand S; Mann JP;
    Hepatol Commun; 2022 Aug; 6(8):1934-1948. PubMed ID: 35411667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variant rs72613567 of HSD17B13 gene reduces alcohol-related liver disease risk in Chinese Han population.
    Chen H; Zhang Y; Guo T; Yang F; Mao Y; Li L; Liu C; Gao H; Jin Y; Che Y; Li Y; Huang J
    Liver Int; 2020 Sep; 40(9):2194-2202. PubMed ID: 33151633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.
    Tang S; Zhang J; Mei TT; Zhang WY; Zheng SJ; Yu HB
    BMC Gastroenterol; 2021 Dec; 21(1):490. PubMed ID: 34930143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD.
    Amangurbanova M; Huang DQ; Loomba R
    Aliment Pharmacol Ther; 2023 Jan; 57(1):37-51. PubMed ID: 36349732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
    Wang P; Wu CX; Li Y; Shen N
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8997-9007. PubMed ID: 32964989
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Kalinowski P; Smyk W; Nowosad M; Paluszkiewicz R; Michałowski Ł; Ziarkiewicz-Wróblewska B; Weber SN; Milkiewicz P; Lammert F; Zieniewicz K; Krawczyk M
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of
    Luukkonen PK; Sakuma I; Gaspar RC; Mooring M; Nasiri A; Kahn M; Zhang XM; Zhang D; Sammalkorpi H; Penttilä AK; Orho-Melander M; Arola J; Juuti A; Zhang X; Yimlamai D; Yki-Järvinen H; Petersen KF; Shulman GI
    Proc Natl Acad Sci U S A; 2023 Jan; 120(4):e2217543120. PubMed ID: 36669104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Metabolite Signatures in Male Carriers of Genetic Variants Associated with Non-Alcoholic Fatty Liver Disease.
    Fernandes Silva L; Vangipurapu J; Oravilahti A; Männistö V; Laakso M
    Metabolites; 2023 Feb; 13(2):. PubMed ID: 36837886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.